ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting

    The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA)  for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis

    Daniela Sieghart1, Farideh Alasti2, Paul Studenic1 and Günter Steiner2, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…
  • Abstract Number: 1433 • 2017 ACR/ARHP Annual Meeting

    Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection

    Muhammad Shipa1, Maria Di Cicco2, Emese Balogh2, Aneela Mian3, Dev Mukerjee4 and Euthalia Roussou2, 1Rheumatology and General internal Medicine, North Middlesex University Hospital NHS trust, London, United Kingdom, 2Barking Havering and Redbridge University hospitals NHS Trust, London, United Kingdom, 3Rheumatology, King's College London, London, United Kingdom, 4Rheumatology, North Middlesex University Trust, London, United Kingdom

    Background/Purpose: Treatment of rheumatoid arthritis (RA) has been revolutionized by the introduction of Tumour Necrosis Factor alpha inhibitors (TNFi). However a significant proportion of patients…
  • Abstract Number: 1434 • 2017 ACR/ARHP Annual Meeting

    COX-2 Inhibitor Contributes Cell Death in Rheumatoid Arthritis Fibroblast-like Synoviocytes Via PI3K/AKT/mTOR Signaling Pathway Triggered By Autophagy

    Sang-Hyon Kim1, Jihye Bang2, Ji-Min Kim1, Chang-Nam Son1, Jin-Nyeong Chae1 and Hye-Jin Jeong3, 1Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea, Republic of (South), 3Department of Rheumatology, Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of (South)

    Background/Purpose: Recently, the possibilities that autophagy regulates apoptosis resistance and hyperplasia of fibroblast-like synoviocytes (FLS) were also presented. The aim of this study is to…
  • Abstract Number: 1435 • 2017 ACR/ARHP Annual Meeting

    Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies

    Yoshiya Tanaka1, Tsutomu Takeuchi2, Satoshi Soen3, Naoki Ishiguro4, Hisashi Yamanaka5, Toshiyuki Yoneda6, Sakae Tanaka7, Takaya Nitta8, Naoki Okubo9, Harry K. Genant10 and Désirée van der Heijde11, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Kindai University Nara Hospital, Ikoma, Japan, 4Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 5Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 6Indiana University School of Medicine, Indianapolis, IN, 7Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Japan, 8Daiichi Sankyo Co., Ltd., Tokyo, Japan, 9DaiichiSankyo CO., LTD., Tokyo, Japan, 10University of California, San Francisco, CA, 11Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by blocking RANKL. Phase 2 (DRIVE) and phase 3 (DESIRABLE) studies…
  • Abstract Number: 1436 • 2017 ACR/ARHP Annual Meeting

    Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab

    Virginia Ruiz-Esquide1, Carla Bastida2, Mariona Pascal3, Jordi Yagüe3, Dolors Soy2 and Raimon Sanmartí1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Pharmacy Service, Hospital Clínic de Barcelona, Barcelona, Spain, 3Immunology Service, Hospital Clínic de Barcelona, b, Spain

    Background/Purpose: Tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). There is great variability in intravenous (iv) TCZ serum concentrations among individuals. Moreover, initial…
  • Abstract Number: 1437 • 2017 ACR/ARHP Annual Meeting

    C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial

    Roy Fleischmann1, Carol A Connell2, Haiyun Fan3 and Sander Strengholt4, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Capelle aan den IJssel, Netherlands

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined high sensitivity C-reactive protein (hsCRP) levels in relation…
  • Abstract Number: 1438 • 2017 ACR/ARHP Annual Meeting

    Is It Necessary to Weight By Weight the Dosage of MTX in RA Patients? Results from Obsevational Analysis of Baseline Data of a Phase III Trial

    Alain Saraux1, Christophe Hudry2, Elena Zinovieva3 and Hélène Herman-Demars3, 1Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, 2AP-HP Hôpital Cochin, Paris, France, 3Medical Department Nordic Pharma, Paris, France

    Background/Purpose: In inflammatory rheumatic diseases, pharmacokinetics of MTX may be modified by patients’ weight [1]. The rheumatologists are though reluctant to prescribe a high dosage…
  • Abstract Number: 1439 • 2017 ACR/ARHP Annual Meeting

    Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies

    Alain Saraux1, René-Marc Flipo2, Bernard Combe3, Jacques Tebib4, Christelle Baffie5, Isabelle Idier6 and Alain Cantagrel7, 1Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, 2Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 3Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, 4Rheumatology, University Hospital, Hospices civils de Lyon, Lyon, France, 5Statistics, Altizem on behalf of Roche, Boulogne Billancourt, France, 6Medical department, Chugai Pharma France, Paris La Defense, France, 7Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France

    Background/Purpose: Tocilizumab (TCZ) as monotherapy (Mono) is nowadays a standard treatment in rheumatoid arthritis (RA) for patients in whom methotrexate (MTX) gives an inadequate response1.…
  • Abstract Number: 1440 • 2017 ACR/ARHP Annual Meeting

    The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated with Tofacitinib

    Kevin Winthrop1, Ann Wouters2, Ernest Choy3, Chudy Nduaka4, Pinaki Biswas2, Lisy Wang5, Jennifer Hodge2, Irina Lazariciu6, Koshika Soma5, Christopher F Mojcik2, Elie Needle7 and William F C Rigby8, 1Oregon Health & Science University, Portland, OR, 2Pfizer Inc, New York, NY, 3CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, Groton, CT, 6QuintilesIMS, Saint-Laurent, QC, Canada, 7Pfizer Inc, Pearl River, NY, 8Geisel School of Medicine at Dartmouth, Lebanon, NH

    Background/Purpose: RA patients (pts) are at increased risk of herpes zoster (HZ), and ACR guidelines recommend vaccination in pts aged ≥50 years prior to starting…
  • Abstract Number: 1441 • 2017 ACR/ARHP Annual Meeting

    Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study

    Shinya Kawashiri1,2,3, Ayako Nishino3,4, Nobutaka Eiraku3, Tamami Yoshitama3, Naoki Matsuoka3, Toshiyuki Aramaki3, Yukitaka Ueki3, Akitomo Okada3, Hiroaki Hamada3, Shuji Nagano3, Keita Fujikawa3 and Atsushi Kawakami1,3, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Departments of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, 4Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Background/Purpose: We have been prospectively investigating therapeutic efficacy of biologic or targeted synthetic DMARDs in patients with rheumatoid arthritis (RA) by ultrasound (US) in Kyushu…
  • Abstract Number: 1442 • 2017 ACR/ARHP Annual Meeting

    Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries

    Jacques-Eric Gottenberg1, Jacques Morel2, Arnaud Constantin3, Thomas Bardin4, Alain Cantagrel5, Bernard Combe2, Maxime Dougados6, René-Marc Flipo7, Alain Saraux8, Thierry Schaeverbeke9, Jean Sibilia10, Martin Soubrier11, Olivier Vittecoq12,13, Gabriel Baron14, Elodie Perrodeau15, Philippe Ravaud14 and Xavier Mariette16, 1CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, 2Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, 3Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, 4Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 5Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, 6Rheumatology, Paris Descartes University, Paris, France, 7Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 8Rheumatology, Brest University Hospital, Brest, France, 9Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, 10Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 11Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 12INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 13Rheumatology Department and INSERM U 905, CHU Rouen, Rouen, France, 14Hôpital Hôtel Dieu, Paris, France, 15Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 16Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France

    Background/Purpose: Little is known regarding the corticosteroid sparing effect of non-TNF biologics in rheumatoid arthritis (RA). Objectives : To compare the corticosteroid sparing effect of…
  • Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting

    Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis

    Zulema Rosales Rosado1,2, Dalifer Freites Núñez2, Cristina Lajas Petisco1, Esperanza Pato Cour1, Leticia Leon2, Judit Font Urgelles1, Juan A Jover Jover1 and Lydia A Alcazar2, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
  • Abstract Number: 1444 • 2017 ACR/ARHP Annual Meeting

    Targeted Therapeutic Delivery to Cartilage with Knottin Proteins

    Emily Girard, Michelle Cook Sangar, Gene Hopping, Fiona Pakiam and James Olson, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

    Background/Purpose: Arthritic diseases affect more than 50 million Americans and, although there are many etiologies, the common manifestation of the disease is pain and limited…
  • Abstract Number: 1445 • 2017 ACR/ARHP Annual Meeting

    Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)

    Dolores Ramos-Bello1, Crisol Alvarez-Quiroga2, Georgina Aguilera Barragán-Pickens3, Angel Javier Pedro Martínez3, Tania Adriana Luna-Zúñiga3, Georgina Martínez-Flores3, Eduardo Saul Acevedo-Castañeda4, Homero López-Ferretis3, Enrique Cuevas-Orta3, Eva Santillan-Guerrero3, Ricardo Moreno-Valdez3, Martín Saldaña-Baarnard3, Marco Ulises Martinez-Martinez5, David Herrera Van Oostdam6, Roberto González-Amaro7 and Carlos Abud-Mendoza8, 1Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico, 2División de Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, UASLP, San Luis Potosí, Mexico, 3Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 4Medicina Interna, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 5Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, 6Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 7Inmunología, Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 8Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico

    Background/Purpose: NLRP3 inflammasome is an intracellular protein complex involved in the production of pro-inflammatory cytokines as IL-1β and IL-18, which has been reported to have…
  • Abstract Number: 1446 • 2017 ACR/ARHP Annual Meeting

    Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission

    Arata Nakajima1, Masato Sonobe1, Shinji Taniguchi1 and Koichi Nakagawa2, 1Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, 2Toho University Sakura Medical Center, Sakura-city, Chiba, Japan

    Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
  • « Previous Page
  • 1
  • …
  • 1299
  • 1300
  • 1301
  • 1302
  • 1303
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology